Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transabdominal ultrasound evaluation of ustekinumab-induced transmural healing in active Crohn's disease
ChiCTR2200055424Phase 4Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ustekinumab in Crohn's disease, sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: Ultrasound response rate at 20 weeks. Started Jan 2022; status: recruiting.
02
Drugs
ustekinumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on ChiCTR2200055424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055424.